For the Inventor, By the Inventor

Enter assignee name

Oryzon Genomics S.a.

USPTO Granted Patents = 33

% Expired Patents = 30.3

CIPO Patents = 1

EPO Patents = 24

Trademarks = 1

Forward Citations = 307

Loading Chart...

Loading Chart...

39 inventors (with patents filed for the assignee):

Alberto Ortega Muñoz (23 out of 24 patents)

Matthew Colin Thor Fyfe (19 out of 19 patents)

Marc Martinell Pedemonte (13 out of 19 patents)

4. Julio Cesar Castro-Palomino Laria (10 out of 16 patents)

5. Tamara Maes (8 out of 9 patents)

6. Nuria Valls Vidal (8 out of 8 patents)

7. Julio Cesar Castro Palomino Laria (7 out of 18 patents)

8. Guido Kurz (6 out of 8 patents)

9. Maria De Los Àngeles Estiarte Martinez (5 out of 5 patents)

10. Jonathan Alleman Baker (4 out of 4 patents)

11. Cristina Mascaro Crusat (3 out of 3 patents)

12. Iñigo Tirapu Fernandez De La Cuesta (3 out of 3 patents)

13. Maria De Los Ángeles Estiarte-Martinez (3 out of 3 patents)

14. Nathalie Guibourt (3 out of 3 patents)

15. Elena Carceller González (3 out of 4 patents)

Core Competencies:

LSD1 Inhibitors

Histone Deacetylase

Borderline Personality Disorder

Solid Tumors

Chemoprobes

Multiple Sclerosis

Demethylase Inhibitors

Hematological Malignancies

Oxidase Inhibitors

Molecular Diagnostics

Flaviviridae

33 patents: Sort by Forward Citations

1. 12673044 - Methods of treating borderline personality disorder (2026-07-07),

2. 12668591 - 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors (2026-06-30),

3. 12564559 - Combinations of LSD1 inhibitors for use in the treatment of solid tumors (2026-03-03),

4. 12195783 - Methods to determine KDM1A target engagement and chemoprobes useful therefor (2025-01-14),

5. 11034991 - Methods to determine KDM1A target engagement and chemoprobes useful therefor (2021-06-15),

6. 11013698 - Combinations of LSD1 inhibitors for the treatment of hematological malignancies (2021-05-25),

7. 10780081 - Method of treating multiple sclerosis employing a LSD1-inhibitor (2020-09-22),

8. 10329256 - (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors (2019-06-25),

9. 10265279 - Combinations of LSD1 inhibitors for use in the treatment of solid tumors (2019-04-23),

10. 10233178 - Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use (2019-03-19),

11. 10221125 - Solid forms (2019-03-05),

12. 10214477 - (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors (2019-02-26),

13. 10202330 - Lysine specific demethylase-1 inhibitors and their use (2019-02-12),

14. 9944601 - (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors (2018-04-17),

15. 9908859 - Lysine demethylase inhibitors for myeloproliferative disorders (2018-03-06),

Company Overview

Oryzon Genomics S.A. is a biotechnology company based in Madrid, Spain, specializing in the development of innovative therapies for neurodegenerative diseases and cancer. The company focuses on epigenetics, leveraging its proprietary technologies to discover and develop novel drug candidates. Oryzon's research aims to address significant unmet medical needs through advanced therapeutic approaches, positioning the company as a key player in the biopharmaceutical sector with a commitment to improving patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

33 Patents

#11 in Madrid

#53 in Spain

#20,130 in the World

Oryzon Genomics S.a.

Forward Citations = 307

39 inventors:

Alberto Ortega Muñoz (23 out of 24 patents)

Matthew Colin Thor Fyfe (19 out of 19 patents)

Marc Martinell Pedemonte (13 out of 19 patents)

4. Julio Cesar Castro-Palomino Laria (10 out of 16 patents)

5. Tamara Maes (8 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Oryzon Genomics S.a.. Retrieved from https://idiyas.com/company/oryzon-genomics-s-a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…